Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE-B

55.400
+0.4500.82%
Volume:3.21M
Turnover:175.24M
Market Cap:19.29B
PE:-37.81
High:55.450
Open:55.050
Low:53.500
Close:54.950
Loading ...

Company Profile

Company Name:
ASCENTAGE-B
Exchange:
SEHK
Establishment Date:
2009
Employees:
567
Office Location:
Suzhou Industrial Park,68 Xinqing Road,Suzhou,Jiangsu Province,China
Zip Code:
215000
Fax:
- -
Introduction:
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

Directors

Name
Position
YANG Da Juan
Chairman of the Board,Executive Director
Benjamin Changqing Ye
Independent Director,Member of the Remuneration and Assessment Committee,Chairman of the Audit Committee
REN Wei
Independent Director,Chairman of the Remuneration and Assessment Committee,Member of the Nomination Committee
David Sidransky
Independent Director,Chairman of the Nomination Committee
Debra Yu
Independent Director,Member of the Remuneration and Assessment Committee
Marina Bozilenko
Independent Director,Member of the Audit Committee
Marc E. Lippman
Independent Director,Member of the Nomination Committee
WANG Shao Meng
Director
SIMON DAZHONG LU
Director,Member of the Audit Committee

Shareholders

Name
Position
YANG Da Juan
CEO
Thomas Joseph KNAPP
Vice General Manager,Advisor
CHEN Chao Man
Corporate Secretary
Raymond Jeffrey Kmetz
Chief Business Officer
DI Yi Fan
Other Senior Executives